NASDAQ:PODD Insulet Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. $221.94 -4.27 (-1.89%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range$215.01▼$224.2250-Day Range$186.40▼$261.9552-Week Range$181.00▼$324.81Volume321,563 shsAverage Volume608,656 shsMarket Capitalization$15.39 billionP/E Ratio352.29Dividend YieldN/APrice Target$290.36 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Stock Forecast (MarketRank)Overall MarketRank™2.15 out of 5 starsMedical Sector434th out of 1,432 stocksSurgical & Medical Instruments Industry52nd out of 137 stocksAnalyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $290.36, Insulet has a forecasted upside of 30.8% from its current price of $221.94.Amount of Analyst CoverageInsulet has only been the subject of 3 research reports in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesInsulet has received 690 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInsulet has received 309 “underperform” votes. (Add your “underperform” vote.)Community SentimentInsulet has received 69.07% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote “Outperform” if you believe PODD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,791,668.00 in company stock.Percentage Held by InsidersOnly 0.90% of the stock of Insulet is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 35.88% in the coming year, from $1.31 to $1.78 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 352.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 352.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.28.Price to Book Value per Share RatioInsulet has a P/B Ratio of 27.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Insulet (NASDAQ:PODD)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Stock News HeadlinesJune 30, 2022 | americanbankingnews.comComparing Penumbra (NYSE:PEN) and Insulet (NASDAQ:PODD)June 29, 2022 | finance.yahoo.comGlobal Wearable Adhesive Market to Reach $6.3 Billion by 2026 - Yahoo FinanceJune 24, 2022 | benzinga.comBTIG Maintains Buy on Insulet, Lowers Price Target to $250 - Benzinga - BenzingaJune 24, 2022 | benzinga.com5 Analysts Have This to Say About Insulet - Benzinga - BenzingaJune 20, 2022 | finance.yahoo.comInsulet (NASDAQ:PODD) shareholders are still up 307% over 5 years despite pulling back 9.2% in the past weekJune 11, 2022 | americanbankingnews.comBrokerages Set Insulet Co. (NASDAQ:PODD) PT at $290.17June 9, 2022 | americanbankingnews.comCharles Alpuche Sells 6,000 Shares of Insulet Co. (NASDAQ:PODD) StockJune 8, 2022 | americanbankingnews.comInsulet (NASDAQ:PODD) Given New $244.00 Price Target at Morgan StanleyJune 7, 2022 | benzinga.comMorgan Stanley Maintains Equal-Weight on Insulet, Lowers Price Target to $244 - Benzinga - BenzingaJune 3, 2022 | finance.yahoo.comOmnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years - Yahoo FinanceJune 3, 2022 | finance.yahoo.comOmnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 YearsJune 2, 2022 | finance.yahoo.comInsulet (PODD) to Expand Base in Malaysia With New FacilityJune 2, 2022 | businesswire.comInsulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference - Business WireSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees2,300Year Founded2000Company Calendar Last Earnings5/05/2022Today6/30/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$290.36 High Stock Price Forecast$350.00 Low Stock Price Forecast$230.00 Forecasted Upside/Downside+30.8%Consensus RatingModerate Buy Rating Score (0-4)2.8 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.629990 Trailing P/E Ratio352.29 Forward P/E Ratio169.42 P/E GrowthN/ANet Income$16.80 million Net Margins3.91% Pretax Margin4.33% Return on Equity15.81% Return on Assets3.85% Debt Debt-to-Equity Ratio3.11 Current Ratio5.98 Quick Ratio4.51 Sales & Book Value Annual Sales$1.10 billion Price / Sales14.01 Cash Flow$1.05 per share Price / Cash Flow211.67 Book Value$8.07 per share Price / Book27.50Miscellaneous Outstanding Shares69,340,000Free Float68,716,000Market Cap$15.39 billion OptionableOptionable Beta0.73 Social Links Insulet Frequently Asked Questions Should I buy or sell Insulet stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Insulet stock. View analyst ratings for Insulet or view top-rated stocks. What is Insulet's stock price forecast for 2022? 10 Wall Street research analysts have issued twelve-month price targets for Insulet's shares. Their PODD stock forecasts range from $230.00 to $350.00. On average, they predict Insulet's share price to reach $290.36 in the next twelve months. This suggests a possible upside of 30.8% from the stock's current price. View analysts' price targets for Insulet or view top-rated stocks among Wall Street analysts. How has Insulet's stock performed in 2022? Insulet's stock was trading at $266.07 at the start of the year. Since then, PODD shares have decreased by 16.6% and is now trading at $221.94. View the best growth stocks for 2022 here. When is Insulet's next earnings date? Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Insulet. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Thursday, May, 5th. The medical instruments supplier reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.17. The medical instruments supplier earned $295.40 million during the quarter, compared to the consensus estimate of $287.99 million. Insulet had a net margin of 3.91% and a trailing twelve-month return on equity of 15.81%. The company's quarterly revenue was up 17.1% on a year-over-year basis. View Insulet's earnings history. What guidance has Insulet issued on next quarter's earnings? Insulet updated its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.23 billion-$1.27 billion, compared to the consensus revenue estimate of $1.24 billion. Who are Insulet's key executives? Insulet's management team includes the following people: Ms. Shacey Petrovic, Pres, CEO & Director (Age 48, Pay $1.72M) (LinkedIn Profile)Mr. Wayde D. McMillan, Exec. VP,CFO & Treasurer (Age 52, Pay $946.57k) (LinkedIn Profile)Mr. Charles Alpuche, Exec. VP & COO (Age 62, Pay $1.03M) (LinkedIn Profile)Mr. John Wodick Kapples, Sr. VP & Gen. Counsel (Age 62, Pay $783.36k)Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 51, Pay $883.8k) (LinkedIn Profile)Ms. Lauren Budden, VP, Chief Accounting Officer & ControllerMs. Deborah R. Gordon CPA, VP of Investor RelationsMr. Michael Spears, Sr. VP of Regulatory Affairs & Compliance (Age 57)Angela Geryak Wiczek, Sr. Director of Corp. CommunicationsMr. Philip Hildale, Sr. VP of Sales & Customer Care What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Insulet's key competitors? Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Teleflex (TFX) and Abiomed (ABMD). View all of PODD's competitors. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). What is Insulet's stock symbol? Insulet trades on the NASDAQ under the ticker symbol "PODD." How do I buy shares of Insulet? Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Insulet's stock price today? One share of PODD stock can currently be purchased for approximately $221.94. How much money does Insulet make? Insulet (NASDAQ:PODD) has a market capitalization of $15.39 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.629990 on an earnings per share basis. How many employees does Insulet have? Insulet employs 2,300 workers across the globe. When was Insulet founded? Insulet was founded in 2000. How can I contact Insulet? Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for Insulet is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at [email protected], or via fax at 978-600-0120. This page (NASDAQ:PODD) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here